Post-marketing Surveillance Study of GSK Biologicals' Pneumococcal Conjugate Vaccine, Synflorix, When Administered According to the Local Prescribing Information in Philippines.

Trial Profile

Post-marketing Surveillance Study of GSK Biologicals' Pneumococcal Conjugate Vaccine, Synflorix, When Administered According to the Local Prescribing Information in Philippines.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 27 May 2016

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate (Primary)
  • Indications Otitis media; Pneumococcal infections; Pneumonia
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 08 Jun 2014 According to ClinicalTrials.gov record, status changed from recruiting to discontinued.
    • 23 Mar 2012 Planned end date changed from 1 Jun 2013 to 1 Apr 2015 as reported by ClinicalTrials.gov.
    • 31 Jan 2011 Planned end date changed from 1 Sep 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top